FDA Adverse Event Injury Summary report: N

VIVAER STYLUS

MDR report key: 15307612 · Received August 26, 2022

Report

Report Number
3011625895-2022-00004
Event Type
Injury
Date Received
August 26, 2022
Date of Event
July 22, 2022
Report Date
August 26, 2022
Manufacturer
AERIN MEDICAL INC.
Product Code
GEI
UDI-DI
08886479300160
PMA / PMN Number
K200300
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NJ, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

DETERIORATION OF MUCOSA PROBABLY EXACERBATED WITH USE OF TOPICAL NASAL DECONGESTANT SPRAY. TOPICAL NASAL DECONGESTANT SPRAYS HAVE BEEN REPORTED TO CAUSE MUCOSAL PERFORATION.

Description of Event or Problem · 0

ON (B)(6) 2022, THE PATIENT WAS TREATED WITH THE VIVAER STYLUS ONLY ON THE RIGHT SIDE. THE SWELL BODY, INTERNAL NASAL VALVE AND THE INFERIOR TURBINATE WERE TREATED. PATIENT HAD FIRST FOLLOW UP VISIT ON (B)(6) 2022 AND AGAIN ON (B)(6) 2022. AT BOTH VISITS, THE PATIENT SHOWED GOOD MUCOSAL HEALING. AT THIRD FOLLOW-UP VISIT ON (B)(6) 2022, MUSCOSA WAS INTACT. PHYSICIAN DISCUSSED SEPTO-TURB OPTION WITH THE PATIENT BECAUSE PATIENT WAS STILL COMPLAINING OF CONGESTION. AT 7-MONTH FOLLOW-UP ON (B)(6) 2022, PATIENT PRESENTED WITH CRUSTING ON SEPTUM AND 1X1 CM2 MUCOSAL PERFORATION IN AREA TREATED WITH VIVAER STYLUS. CARTILAGE WAS INTACT. THE PATIENT REPORTED USING AFRIN OFF AND ON FOR PAST MONTH. PHYSICIAN PLANS TO MOVE FORWARD WITH SEPTOPLASTY PROCEDURE TO ADDRESS PERSISTENT CONGESTION. TOPICAL NASAL DECONGESTANT SPRAYS HAVE BEEN REPORTED TO CAUSE MUCOSAL PERFORATION. THE DETERIORATION OF THE MUCOSA IS PROBABLY RELATED TO THE COMBINATION OF THE RADIOFREQUENCY TREATMENT OF THE TISSUE IN THE AREA FOLLOWED BY USE OF AFRIN.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2088006 VIVAER STYLUS RADIOFREQUENCY PROBE GEI AERIN MEDICAL INC. FG722 08886479300160

Patients

Seq Age Sex Outcome Treatment
1 65 YR Male Other